Eli Lilly and Company
LLY
$939.47
-1.65%
Eli Lilly and Company is a global pharmaceutical leader focused on developing and commercializing medicines across key therapeutic areas including cardiometabolic health, immunology, neuroscience, and oncology. The company is a dominant player in the lucrative GLP-1 market, distinguished by its blockbuster drugs Mounjaro and Zepbound for diabetes and obesity, which have propelled it to the forefront of the industry. The current investor narrative is overwhelmingly centered on its leadership in the obesity drug race, recent FDA approval for an oral weight-loss treatment, and strategic use of its massive cash flows to fund ambitious bets in AI-driven drug discovery and neuroscience acquisitions, positioning it for sustained long-term growth beyond its current blockbusters.…
LLY
Eli Lilly and Company
$939.47
Related headlines
LLY 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1221.31 and implied upside of +30.0% versus the current price.
Average Target
$1221.31
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$752 - $1221
Analyst target range
Analyst coverage is robust with 11 firms providing estimates, and the institutional sentiment remains overwhelmingly bullish, as evidenced by recent actions from major banks like JP Morgan and Morgan Stanley reiterating Overweight ratings. The consensus recommendation is a Strong Buy, with the average target price derived from revenue and EPS estimates implying significant confidence in the growth story, though a specific consensus price target is not provided in the data. The target range for estimated EPS is wide, from $54.48 to $66.38, reflecting differing assumptions about market penetration, competitive dynamics, and pipeline success. The high end of the EPS range likely assumes dominant market share retention, successful pipeline conversions, and sustained pricing power, while the low end may factor in increased competition, payer pressure, or clinical setbacks. The recent institutional ratings show a mix of Buy reiterations and one downgrade to Reduce, indicating generally strong conviction but not unanimous optimism, with the wide EPS target spread underscoring the high uncertainty inherent in forecasting a company experiencing such transformative growth.
Bulls vs Bears: LLY Investment Factors
The bull case, anchored in explosive 42.6% revenue growth and expanding 34.4% net margins, currently holds stronger evidence due to the tangible financial outperformance and dominant market position. However, the bear case presents a formidable counterpoint centered on a precarious 46.8x trailing PE premium and a sharp 31.46% technical drawdown from highs. The single most important tension in the investment debate is whether the company's extraordinary growth trajectory can sustain long enough to justify its premium valuation and absorb its increased leverage, or if a deceleration in GLP-1 momentum will trigger severe multiple compression and validate the recent technical breakdown.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue surged 42.6% YoY to $19.29B, driven by the dominant GLP-1 franchise. This acceleration from $12.73B in Q1 2025 demonstrates powerful, sustained momentum.
- Exceptional & Expanding Profitability: Net margin expanded to 34.4% in Q4 2025 from 32.6% a year ago, with gross margin reaching 85.05%. This operating leverage from high-margin blockbusters fuels massive cash flow, with TTM FCF of $8.97B.
- Dominant Market Position & Pipeline: Recent FDA approval for an oral weight-loss drug and a $10B AI/neuroscience investment solidify its leadership beyond current GLP-1 drugs. The Cardiometabolic segment alone generated $13.18B in Q4.
- Strong Analyst Conviction: The consensus is a Strong Buy from 11 analysts, with recent major bank reiterations of Overweight ratings. The wide but high EPS target range ($54.48-$66.38) reflects confidence in the long-term growth story.
Bearish
- Premium Valuation vs. Peers: A trailing PE of 46.8x is a significant premium to the typical drug manufacturer industry average in the low-to-mid 20s. This leaves the stock vulnerable to multiple compression if growth expectations falter.
- Sharp Technical Correction: The stock is down 31.46% from its 52-week high and trades near 55% of its 52-week range ($623.78-$1133.95). Negative 3-month momentum of -11.67% signals a breakdown from the prior uptrend.
- Increased Financial Leverage: Debt-to-equity has risen to 1.60 to fund growth and acquisitions. While supported by a 77.78% ROE, this increases financial risk if the growth engine slows unexpectedly.
- Revenue Concentration Risk: Growth is heavily reliant on the Cardiometabolic (GLP-1) segment. Any clinical, competitive, or regulatory setback in this area could disproportionately impact the top line, which grew 42.6% YoY.
LLY Technical Analysis
The stock is in a pronounced corrective phase within a powerful longer-term uptrend. Over the past year, LLY has delivered a substantial 30.32% gain, yet it is currently trading at approximately 55% of its 52-week range ($623.78 to $1133.95), indicating a significant retreat from its highs and suggesting a potential value opportunity after a period of overextension. Recent momentum has turned sharply negative, with the stock down 6.04% over the past month and 11.67% over the past three months, a stark divergence from the strong yearly performance that signals a meaningful pullback or consolidation. This negative short-term momentum is further evidenced by a relative strength reading of -6.50% versus the S&P 500 over one month. Key technical support is anchored at the 52-week low of $623.78, while formidable resistance sits at the 52-week high of $1133.95; a decisive break below the recent March low near $878 could signal a deeper correction, whereas reclaiming the $1100 level would reaffirm the primary bull trend. With a beta of 0.50, the stock exhibits roughly half the volatility of the broader market, which historically provided defensive characteristics but has not insulated it from the recent sharp drawdown of -31.46% from its peak.
Beta
0.50
0.50x market volatility
Max Drawdown
-30.4%
Largest decline past year
52-Week Range
$624-$1134
Price range past year
Annual Return
+30.3%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | -6.0% | +2.6% |
| 3m | -11.7% | -2.3% |
| 6m | +12.7% | +2.6% |
| 1y | +30.3% | +27.3% |
| ytd | -13.0% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Revenue growth is exceptionally robust and accelerating, driven by the company's GLP-1 franchise. For Q4 2025, revenue reached $19.29 billion, representing a staggering 42.6% year-over-year increase, and this follows sequential quarterly revenue growth from $12.73B in Q1 to $19.29B in Q4, demonstrating powerful momentum. The Cardiometabolic segment, which includes the flagship obesity and diabetes drugs, is the primary engine, contributing $13.18 billion in the latest period. Profitability is immense and margins are expanding impressively; Q4 2025 net income was $6.64 billion, yielding a net margin of 34.4%, while the gross margin stood at an exceptional 85.05%. This represents significant expansion from the year-ago Q4 net margin of 32.6% and gross margin of 82.2%, highlighting the operating leverage from surging sales of high-margin products. The balance sheet is strong with ample liquidity and cash generation, though leverage has increased to fund growth. The company boasts a current ratio of 1.58 and generated trailing twelve-month free cash flow of $8.97 billion. The debt-to-equity ratio of 1.60 reflects strategic borrowing, but this is comfortably supported by an extraordinary return on equity of 77.78%, indicating highly efficient use of capital.
Quarterly Revenue
$19.3B
2025-12
Revenue YoY Growth
+0.42%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$9.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 46.8x, while the forward PE is significantly lower at 22.3x, indicating the market expects a near-doubling of earnings, which aligns with the explosive growth trajectory of its GLP-1 drugs. Compared to the broader drug manufacturer industry, LLY's trailing PE of 46.8x represents a significant premium, as typical industry averages are often in the low-to-mid 20s; this premium is justified by its superior growth profile, blockbuster pipeline, and market-leading position in the highest-growth therapeutic category. Historically, the stock's own trailing PE has ranged widely, from around 30x to over 200x during periods of transition; the current 46.8x is above the median of its multi-year range but well below the extreme highs seen in 2024, suggesting expectations are high but not at peak optimism, pricing in continued execution but leaving room for multiple compression if growth decelerates.
PE
46.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -2221x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the company's elevated valuation (46.8x trailing PE) which demands flawless execution of its high-growth narrative; any deceleration from the current 42.6% revenue growth rate could trigger significant multiple compression. While profitability is robust with a 34.4% net margin, the debt-to-equity ratio of 1.60 reflects increased leverage to fund its ambitious pipeline bets, introducing balance sheet risk if free cash flow generation ($8.97B TTM) were to weaken. Furthermore, revenue concentration in the Cardiometabolic segment, which drove $13.18B in Q4 sales, creates overdependence on the GLP-1 franchise's continued success against intensifying competition.
Market & Competitive Risks: The stock trades at a substantial premium to industry PE averages, making it highly susceptible to sector-wide valuation compression, particularly in a rising interest rate environment. Competitive disruption is a clear and present danger, as news highlights a direct 'one-two punch' battle with Novo Nordisk for obesity drug dominance. Regulatory headwinds, exemplified by the 100% tariff threat for non-exempt pharma companies, create a bifurcated market, though LLY's reported exemption provides a temporary moat. The stock's low beta of 0.50 suggests less macro volatility, but it has not prevented a severe -31.46% drawdown, indicating company-specific growth concerns are the dominant risk driver.
Worst-Case Scenario: The worst-case scenario involves a combination of faster-than-expected competitive encroachment on its GLP-1 drugs, leading to missed revenue estimates, coupled with a clinical setback in its high-profile pipeline (e.g., neuroscience acquisitions). This would catalyze a wave of analyst downgrades, compressing the forward PE from 22.3x towards the industry average, while technical selling accelerates a break below the March low of ~$878. A realistic downside could see the stock re-testing its 52-week low of $623.78, representing a potential loss of approximately -34% from the current price of $939.47, mirroring the recent peak-to-trough decline.